Human embryonic stem cells (hESCs) are extremely delicate, and survive poorly under suboptimal culture conditions, severely restricting long-term studies and practical applications. Thus, a protective agent that promotes stem cell survival is urgently needed. In this study, we evaluated the protective effects of stemazole in single-cell and starved hESC cultures. Colony formation was quantified by alkaline phosphatase and immunofluorescence staining, while apoptosis was assessed by flow cytometry and TUNEL assay. Expression of hESC and other stem cell markers was evaluated by western blot, RT-PCR, and qPCR. We found that stemazole enhanced clonal expansion from single cells in dose-dependent fashion and clearly decreased apoptosis from 54.1% to 25.2%. Furthermore, the drug reduced apoptosis from 43.6% to 8.4% over 15 h of starvation, with 66% of stemazole-treated cells remaining viable after 2 weeks of starvation. Importantly, starved cells protected with stemazole retained the same proliferation and differentiation properties as cells in normal culture. In conclusion, stemazole significantly promotes survival of stem cells in single-cell or starvation cultures without compromising stemness and pluripotency.
Introduction
Human embryonic stem cells (hESCs) derived from the inner cell mass of early blastocysts are self-renewing, pluripotent cells that proliferate and differentiate into a variety of somatic cells [1] . Consequently, these cells are a critical resource for tissue regeneration and transplantation, which are highly promising therapies for many degenerative diseases and injuries that are currently untreatable [2, 3] . Importantly, hESCs and derivative cells differentiate autonomously and may be genetically manipulated to deliver specific genes at target sites.
However, hESCs are sensitive to environmental signals or conditions that derail the developmental Abbreviations BSA, bovine serum albumin; DMSO, dimethyl sulfoxide; hESC, human embryonic stem cell; hiPSC, human induced pluripotent stem cell; TUNEL, TdT-mediated dUTP nick-end labeling.
program [4] [5] [6] [7] [8] . For example, hESCs survive extremely poorly and are prone to apoptosis upon disaggregation into single cells, preventing rapid expansion of cultures [9, 10] . In turn, the instability of single-cell cultures is a critical issue, as hESC-based technologies rely on efficient proliferation and passaging. In addition to cellcell and cell-matrix interactions, hESCs also require growth factors, which are conventionally supplied in vitro using serum or as basic growth factor [11, 12] . However, such supplements are inconsistently applied and are usually complex and variable in composition. Indeed, unknown factors that may be present in these supplements may elicit specific differentiation programs contrary to the intended outcome [13, 14] . Hence, an effective and low-cost agent that stabilizes single-cell cultures in a well-defined state would greatly accelerate basic and applied research.
Recently, several groups reported new strategies that allow robust hESC self-renewal. For instance, Watanabe et al. [15] demonstrated that inhibition of Rho-associated kinase by the small-molecule Y-27632 prevents massive cell death due to cell dissociation during routine passage. Such small molecules that control stem cell fate have obvious advantages of being cell permeable, nonimmunogenic, cost-effective, and easily synthesized, preserved, and standardized. Moreover, the effects of these molecules are often reversible and finely tunable by dose [16] [17] [18] [19] . Indeed, these compounds have enabled better understanding of stem cell and regenerative biology, as well as better control of cell proliferation and differentiation [20, 21] . Accordingly, we attempted to identify new molecules that could replace serum and basic growth factor and allow maintenance of hESCs over single-cell passaging or severe culture conditions. Of the tens of thousands compounds we screened, stemazole was found to promote cell viability in neural stem cells, pancreatic stem cells, and hESCs [22] . We now demonstrate that stemazole promotes resistance to apoptosis, and enables long-term maintenance of hESCs, especially under severe culture conditions, including starvation and cell disaggregation. Importantly, we found stemazole to dramatically improve hESC survival and clonal expansion without compromising self-renewal, pluripotency, and genetic integrity. Collectively, the data highlight the value of stemazole as a new tool for single-cell or starvation culture of hESCs.
Results

Stemazole promotes hESC survival
In a previous study, we demonstrated that stemazole, with molecular structure 4-(4-(5-mercapto-1,3,4-oxadiazol-2-yl)phenyl)thiosemicarbazide (Fig. 1A) , promotes proliferation of human hippocampal and other stem cells. In this study, stemazole and six derivatives obtained by oriented synthesis were assessed by quantitative structure-activity relationship assays (Fig. 1B) to identify a molecule most suitable for maintaining hESCs. Of the seven compounds tested, only stemazole was found to promote cell survival and viability in dose-dependent fashion, with effective concentration of 10-100 lM (Fig. 1C) .
Stemazole enhances survival of disaggregated hESCs
Stemazole (10, 30, and 100 lM) significantly promoted colony formation in single-cell hESC cultures in dosedependent fashion (P < 0.01 vs DMSO, Fig. 2A ). Like typical hESCs, single-cell hESCs cultured with stemazole formed adherent and monoclonal colonies that expressed alkaline phosphatase and Oct-4 ( Fig. 2B) . Alkaline phosphatase staining also indicated that stemazole increased the number and size of colonies (Fig. 2C ), especially at day 8 (P < 0.01 vs cultures without stemazole, Fig. 2D,E) . In contrast, most hESCs did not survive in single-cell cultures without stemazole. Taken together, the results indicate that stemazole promotes survival of disaggregated hESCs. In addition, stemazole promotes cell proliferation of neural stem cells (Fig. 3A) and hiPSCs (Fig. 3B ).
Stemazole prevents apoptosis in disaggregated hESCs
Similar to Y-27632, which is currently widely used to increase hESCs survival as a Rock inhibitor, stemazole enhanced attachment in disaggregated H9 cells and elicited formation of large, nearly round colonies (Fig. 4A) . In contrast, disaggregated cells cultured without stemazole (only the same amount of DMSO, the solvent of stemazole) did not form the normal colonies in culture media. Fluorescence-activated cell sorting after staining with annexin V and propidium iodide showed that stemazole or Y-27632 dramatically decreased apoptosis from 38.53% to 7.83%, or 6.92%, respectively (Fig. 4B,C) , suggesting that the compound confers resistance to apoptosis in disaggregated hESCs. However, these two drugs did not show any additive or synergistic effects on the cell survival (Fig. 4B,C) .
When stemazole was used to prevent from apoptosis induced by cell sorting procedure, the colony number and cell growth of sorted hESCs were found to be promoted significantly (Fig. 5) . 
Stemazole inhibits apoptosis in starved cultures
By tracking H9 cells over 15 h, we found that starvation rapidly induced apoptosis and accumulation of cell debris in cells cultured without stemazole. However, these events were significantly delayed and inhibited in cells exposed to stemazole (Fig. 6A ). For instance, apoptosis at 6 h was over 30% in cells cultured without stemazole, but less than 1% in cells exposed to stemazole (P < 0.01, Fig. 6C ). We also found that nuclei disintegrated and apoptotic bodies formed with starvation in the absence, but not in the presence, of stemazole ( Fig. 6B ), noting that formation of apoptotic bodies by nuclear pycnosis is a hallmark of apoptosis. After two weeks of starvation in the presence of stemazole, most cells remained adherent and brightly stained (Fig. 6D) . Indeed, viability was 66% in cells exposed to stemazole, but less than 4% in cells starved without stemazole (Fig. 6E) , indicating that the compound promotes survival and inhibits apoptosis in the long term.
To further investigate apoptosis resistance, cells were also examined after 15 h of starvation by fluorescenceactivated cell sorting based on staining with TUNEL and annexin V/propidium iodide. Annexin V staining, a measure of membrane ectropion, significantly decreased from 43.63% in control cells to 8.39% in cells exposed to stemazole (Fig. 6F,G) . Similarly, TUNEL staining, a measure of DNA fragmentation, significantly decreased from 34.75% in the former to 12.26% in the latter (P < 0.01, Fig. 6H,I ). Taken together, the data indicate that stemazole markedly decreases starvation-induced apoptosis. As stemazole plays similar role in survival of hESCs with Y-27632, a Rho/Rock inhibitor, we tested whether Rho/Rock signaling pathway was also associated with resistance to starvation-induced apoptosis. We found that stemazole inhibited the activation of Rho/Rock (Fig. 6J) , with activated Rho reduced to 45.2% (Fig. 6K ).
Stemazole preserves stemness in hESCs
As pluripotency and self-renewal are the defining and most valuable properties of hESCs, we evaluated stemness in hESCs starved in the presence of stemazole. We found that the compound stabilized the expression of the critical pluripotency markers, Oct-4 and E-cadherin, at levels significantly higher than in control cells (Fig. 7A,B) . Stemazole also stabilized the expression of other hESC markers, including Sox-2, FGF4, KLF4, and Rex1, but not Nanog (Fig. 7C ). Proliferative activity, as measured by Ki67 expression, was similar between hESCs cultured in rich media (97%) and hESCs starved for 15 h in the presence of stemazole (90%, Fig. 7D ). In contrast, Ki67 expression was significantly lower in cells starved without stemazole (47%, Fig. 7E ). Embryoid body formation was observed in all cells after 15 h of starvation, although diameter and number were significantly different between cells starved with or without stemazole (Fig. 7F-H) . Finally, cultures starved in the presence of stemazole expressed similar levels of pluripotency markers as normal cultures, including the endoderm markers CK8 and CK18, the mesoderm markers Brachyury and MSX1, and the ectoderm markers GFAP, Pax6, and MAP2 (Fig. 7I) . The further determination indicated that comparing with non-treatment, stemazole did not change the karyotypes of H1, H9, and hiPS cells compared with stemazole pretreatment (Fig. 8) .
Collectively, the data strongly demonstrate that stemazole promotes hESC survival and resistance to apoptosis without compromising self-renewal, proliferative capacity, and pluripotency.
Discussion
At present, hESCs remain extremely difficult to culture in vitro, a situation that greatly limits extensive application. In particular, hESCs undergo significant cell death upon disaggregation into single cells or upon starvation, precluding differentiation, rapid expansion, and genetic manipulation [1] . Thus, small molecules that precisely control hESCs may significantly advance the state of the art. Accordingly, we have screened thousands of compounds, and identified stemazole, a small molecule that may stabilize hESCs by inhibiting apoptosis.
Indeed, stemazole was found to promote survival, attachment, and apoptosis resistance in disaggregated hESCs. In addition, stemazole enhanced, in a dosedependent manner, the formation, number, and size of colonies in H9 single-cell cultures. We note that stemazole is the only small molecule known so far to elicit colony formation from single hESCs. To address more practical issues, we also examined the protective effects of stemazole in the absence of basic growth factor or during starvation. Notably, we found that the compound also delayed and blocked apoptosis during starvation, which is otherwise well known to induce severe apoptosis characterized by marked nuclear and DNA fragmentation, formation of apoptotic bodies, membrane ectropion, and other events. Thus, stemazole appears to potently promote long-term survival and maintenance in starved hESCs and may thereby enable a range of hESC applications. Importantly, stemazole also stabilized embryoid body formation and expression of Oct-4, E-cadherin, and Ki67, suggesting that the compound prevents hESC apoptosis due to disaggregation or starvation without compromising selfrenewal, proliferation, and pluripotency.
In addition, we previously demonstrated that stemazole is neuroprotective in vivo, and may protect against Alzheimer's disease, based on studies in a rat model [23] , and Parkinson's disease, based on its neuroprotective effects on an impaired dopamine system [24] . Taken together, these indicate that stemazole is a promising agent to control hESCs and thus to facilitate hESC production and implantation. Ultimately, stemazole may advance regenerative and degenerative medicine.
In summary, we have demonstrated that stemazole promotes survival and colony formation in disaggregated hESCs, protects hESCs from starvation-induced apoptosis, and supports long-term hESC maintenance without compromising self-renewal and pluripotency. Hence, stemazole may provide a new strategy to culture hESCs. As the compound has been found in preliminary studies to potentially protect multiple stem cell lines, we now intend to more fully characterize its activities in other stem cell lines, by itself or in combination with other compounds. In addition, the direct targets of stemazole and the underlying mechanisms require further systematic studies, although Rho/Rock signaling pathway was implicated in apoptosis resistance. In the long term, stemazole appears to have great potential as an agent to precisely control embryonic stem cell fate in vitro and in vivo. 
Materials and methods
Maintenance culture of hESCs basic fibroblast growth factor (R&D Systems, Minneapolis, MN, USA). Cells were grown at 37°C and 5% CO 2 , and media were refreshed daily. To passage, hESC colonies were washed three times with DMEM (Hyclone) and digested at 37°C for 5-7 min with DMEM/F12 containing 1 mgÁmL À1 collagenase IV (Sigma). The enzyme was removed as cells began to dissociate from the dish bottom. Cells were then washed three times with DMEM, collected, dispersed into small clusters by gentle pipetting, and transferred to freshly inactivated mouse embryonic fibroblasts seeded on gelatin-coated dishes. Cells were passaged at 1 : 4 split ratio. To store, hESC colonies were recovered en bloc without further dissociation from a 6-cm culture dish, suspended in 1 mL ice-cold culture medium supplemented with 10% DMSO and 30% knockout serum replacement, and quickly frozen to À80°C in a freezing box. Samples were then moved to liquid N 2 the following day.
Stemazole treatment of disaggregated hESCs
H9 cells were detached from the feeder layer and partially dissociated as described. Contaminating mouse embryonic fibroblasts were then removed by incubating for 2 h at 37°C in a gelatin-coated plate containing maintenance medium, which induces mouse embryonic fibroblasts, but not hESCs, to adhere to the dish bottom. H9 clumps were then recovered by centrifugation, washed with DMEM, incubated at 37°C for 5 min in 0.25% (wt/vol) trypsin/ EDTA (Invitrogen, Carlsbad, CA, USA), dissociated into single cells by pipetting, and passed through a 70-mm cell strainer (BD Falcon, Franklin, NJ, USA). For quantitative structure-activity relationship testing, dissociated cells were seeded at 1000 cells per well onto a mouse embryonic fibroblast feeder layer (100 cells per well) in a flat-bottomed 384-well back plate, and treated for 4 days with serial dilutions of stemazole and derivatives, using 10 wells per treatment. To measure clone formation rate, dissociated cells were seeded at 100 cells per well onto a mouse embryonic fibroblast feeder layer (100 cells per well) in a flat-bottomed 96-well plate and treated for 8 days with serial dilutions of stemazole. To assess clone formation, a single dissociated cell was seeded onto a mouse fibroblast feeder layer (100 cells per well) in a flat-bottomed 96-well plate and exposed to 100 lM stemazole for 8 days. To assess clone formation in a population, dissociated cells were seeded at 1 9 10 5 cells per well onto a mouse embryonic fibroblast feeder layer (1 9 10 4 cells per well) in a 24-well plate and incubated with 100 lM stemazole for 8 days. For annexin V staining and fluorescence-activated cell sorting, dissociated cells were seeded at 5 9 10 5 cells/dish onto a mouse embryonic fibroblast feeder layer (5 9 10 4 cells/well) in a 60-mm dish and treated with 100 lM stemazole for 2 days. The day on which hESCs were seeded was defined to be day 0.
Stemazole treatment of starved hESCs
Passaged H9 cells were seeded on mouse embryonic fibroblasts for 3-4 days in maintenance medium, rinsed three times with DMEM, transferred to DMEM/F12 culture medium without knockout serum replacement and basic fibroblast growth factor, but supplemented with 2 mM L-glutamine, 0.1 mM b-mercaptoethanol, 1% nonessential amino acids, 100 unitsÁmL À1 penicillin, 100 unitsÁmL À1 streptomycin, and 100 lM stemazole. DMSO was used as negative control. Cells were starved for various days at 37°C and 5% CO 2 . 
Cell viability assay
Cell viability was quantified by CellTiter-Glo Ò , which is based on the luciferase/luciferin reaction. In this assay, the luminescence produced in the presence of Mg 2+ and ATP is proportional to the amount of ATP present, an indicator of cellular metabolic activity. Accordingly, the luminescent signal is directly proportional to the number of viable cells. Briefly, CellTiter-Glo Ò reagent was directly added to cultures, and luminescence was measured on a Multilabel Counter (VICTOR3TM 1420; Perkin Elmer, Waltham, MA, USA) after mixing and incubating for 10 min at ambient temperature.
Fluorescence-activated cell sorting 
TUNEL assay
After 15 h of starvation, cells were gently rinsed three times with DMEM, fixed in 4% (wt/vol) paraformaldehyde, and stained with TUNEL using In Situ Cell Death Detection Kit (Roche, Basel, Switzerland), following the manufacturer's instructions. 
Alkaline phosphatase and immunofluorescence staining
Rho activation assay
Using a Rho activation assay kit (Millipore, Boston, MA, USA), a pull-down assay for detecting Rho activity was performed according to the manufacturer's instructions from cell lysates of H9 cells. Total protein concentrations were detected and equalized in control and treatment groups. b-Tubulin protein was used as the internal control. After whole-cell lysates were incubated with agarose-conjugated Rhotekin RBD, agarose beads were boiled in SDS/ PAGE sample buffer for releasing active Rho. After precipitation, samples were applied for western blotting with a specific antibody for Rho.
RT-PCR and qPCR
RNA was extracted using RNeasy Plus Mini Kit (Qiagen, Dusseldorf, Germany) according to the manufacturer's instructions. For RT-PCR, targets were amplified with Taq DNA polymerase (Promega, Madison, WI, USA) on a Gene-Amp PCR System 9700 (Applied Biosystems, Foster City, CA, USA) by denaturation at 95°C for 5 min, followed by an appropriate number of cycles at 95°C for 30 s, annealing at 58-70°C for 30 s, and final extension at 72°C for 10 min. For qPCR, targets were amplified with SYBR Green qPCR Mix (TaKaRa, Tokyo, Japan) on an Agilent StrataGene Mx3000P (Stratagene, Santa Clara, CA, USA) by denaturation at 95°C for 5 min, followed by an appropriate number of cycles at 95°C for 15 s, annealing at 59-71°C for 1 min, and final extension at 72°C for 10 min. Primer sequences are listed in Table S1 .
Embryoid body formation and in vitro differentiation
hESCs cultured in rich media or starved for 15 h in the presence of 100 lM stemazole or DMSO were digested with collagenase IV, dispersed into small clusters by gentle pipetting, and transferred to ultra-low-attachment dishes containing embryoid body-inducing media, which consisted of DMEM/F12, 20% knockout serum replacement, 2 mM L-glutamine, 0.1 mM b-mercaptoethanol, 1% nonessential amino acids, 100 unitsÁmL À1 penicillin, and 100 unitsÁmL À1 streptomycin. Cells were grown at 37°C and 5% CO 2 , and media were refreshed every other day.
iPS culture and cell counting iPSCs were cultivated on Matrigel-coated (1 : 100 dilution) cell culture plates with E8 medium and passaged by digestion into small clusters using 0.5 mM EDTA (Life Technologies, Waltham, MA, USA). About 2 9 10 4 live cells (counted using Cellometer) were plated onto the Matrigelcoated 12-well cell culture plate. Two conditions were tested: with stemazole (ST group) and without stemazole (DMSO group). The following day, the culture medium was replaced with fresh E8 medium. Subsequently, the culture medium was changed every other day. At 80-90% confluence, the cells were ready for the next passage. At the indicated time points, cells were digested with Accutase (Life Technologies) into single cells and counted using Cellometer for the cell growth curve analysis.
Cell sorting
To observe the recovery of PSC in stemazole post-cell sorting, the PSCs, including H1 and H9 cells, were digested into single cells with Accutase (Life Technologies) and sorted by BD FACS Aria (Becton Dickinson, Franklin, NJ, USA); the gated cells were plated onto mitomycintreated feeder; and two conditions were tested: with stemazole and without stemazole. The formation of single-cell clone was assayed by alkaline phosphatase staining.
Karyotype analysis
Karyotype analyses of the H1, H9, and iPSCs were carried out after stemazole treatment another five passages. These cells were treated with 10 lgÁmL À1 of colcemid (Gibco) for 90 min at 37°C, then trypsinized by hypotonic solution KCl 0.075 M, and fixed with Carnoy's fixative. Cells were dropped on a microscope glass slide to dry. Metaphase cells were G banded using Wright staining.
Statistical analysis
Data were collected from at least three independent experiments, are reported as mean AE SD, and were analyzed by Student's t-test for independent samples. P < 0.05 was considered significant.
